The European Commission has approved Epidyolex (cannabidiol) as an add-on therapy to clobazam (brand names Onfi and Sympazan)…
Articles by José Lopes, PhD
Targeting a specific brain area called the reticular thalamic nucleus may be an effective treatment for non-convulsive seizures in children…
Distinct mutations in the SCN1A gene are associated with different degrees of impairment in specific brain nerve cells as…
Add-on oral treatment with Epidiolex (cannabidiol) significantly lowered the frequency of convulsive seizures in patients with Dravet syndrome,…
Vagus nerve stimulation (VNS) therapy can lead to more than $77,000 in cost savings over five years for patients with…
A new system of vagus nerve stimulation (VNS) therapy was implanted in the first patient with drug-resistant epilepsy, as part…
Continuous use of antiepileptic medications leads to an increased risk of Alzheimer’s disease and dementia, according to a recent study. These…
Current first-line therapies for Dravet syndrome have limited effectiveness, but treatment candidates now undergoing clinical testing show significant promise, researchers…
An RNA splicing technique that Stoke Therapeutics is developing led to the production of a protein that’s lacking in Dravet…
Increased brain levels of a protein involved in inflammation were found to suppress seizures in mice, a finding that may have…